our commitment is real
Relentless in our mission to positively impact the rare disease community, we seek to include individuals and their families in every aspect of what we do. And that’s because at Ovid, we believe that having a deep and true understanding of what it’s like to live with a rare neurological disease is key to addressing significant unmet needs.
Here, the patient community is our community. Each relationship we foster brings us closer and closer to making meaningful medicines readily available to those who may benefit.
Hear more about our community-first approach to rare neurological diseases:
the who behind our why
Meet Rhys, a young boy with Angelman syndrome
“Rhys loves everyone unconditionally. He can make anyone smile, especially on the days you need it most. He has a heart of gold.”
– Rob & Melissa, Rhys’ parents
We are from Boise, Idaho, a chaotic family of six but we wouldn’t have it any other way. Dad (Rob) is a football coach and fun dad and mom (Melissa) is a stay-at-home mom, chauffeur, maid etc. McCall (age 9) is the only girl and our artist. Bodie (age 7) is our athlete and comic relief. Rhys (age 5, deletion +) is our reason. He is the best thing that ever happened to our family. Last, but not least is our little surprise Archer (age 1) who is keeping us on our toes!
Our family would do anything to be able to hear Rhys talk. We want him to argue with his siblings. We want him to play football with his brothers. We want him to not have the debilitating seizures that wreak havoc on his accomplishments. However, some things about Rhys do not need changed. Rhys loves everyone unconditionally. He can make anyone smile, especially on the days you need it most. He has a heart of gold.
We are so excited for the work Ovid is doing, and we are proud to be a part of such an amazing Angelman community.
take a deeper look
engagement powered by purpose
Partnering with patient advocacy groups and foundations puts us on the ground with those fighting for a better future. Working shoulder to shoulder, our relationships with these organizations are personal—united in our passion to make meaningful change happen.
Ovid is driven by the passion to improve the lives of individuals and their families by working to develop new medicines for individuals living with rare and serious illnesses. As a company, we want to bring our medicines to the largest numbers of people who may potentially benefit from them. At the same time, we have a duty to balance this desire while ensuring that our investigational drugs are both safe and effective before making them available outside of the controlled setting of clinical studies.
Currently, Ovid Therapeutics does not have an Expanded Access Program for its pipeline compounds, but is evaluating the potential for an expanded access program for OV101 (gaboxadol) and soticlestat and will work with regulators to determine the best path forward.
We understand that individuals with Angelman syndrome, Fragile X syndrome and rare epilepsies do not have many options to address their medical needs. Investigational clinical studies are the fastest path to bring forward a potential treatment these rare neurological conditions. Because our goal is to help as many individuals as possible, as quickly as possible, access to the investigational therapy outside of a clinical trial must not adversely impact or delay the clinical studies involving the investigational therapy so that we can meet rigorous medical and regulatory requirements before making a potential treatment option widely available.
At times, a physician may seek access to therapeutics in early development, not yet approved by regulatory agencies, for an individual with a life-threatening or serious disease who has exhausted all medical options. This use of a drug candidate outside of the context of a clinical trial is called expanded access, among other names.
The following is additional information regarding Ovid’s expanded access policy in accordance with the 21st Century Cures Act:
⦁ Contact Information: If you have any questions regarding Ovid’s expanded access policy in general, please contact email@example.com. If you have any questions regarding potential participation in Ovid’s clinical trials, please contact us by email at firstname.lastname@example.org.
⦁ General Criteria: If Ovid opens an expanded access program, we will update this policy and provide appropriate details.
⦁ Response Timing: If you contact Ovid as described above, we will acknowledge receipt within five business days.
Our studies are exploring potential treatments that could be the first to make a meaningful impact in the lives of individuals with rare neurological diseases.
grants, sponsorships and charitable contributions
Driven by our passion, Ovid aims to positively impact the lives of patients, communities and healthcare workers by supporting various various activities and organizations.